Antoinette S. Gomes

Dr. Antoinette S. Gomes

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CBCarolyn D Britten
Carolyn D Britten
AGAntoinette S. Gomes
Antoinette S. Gomes
ZWZev A Wainberg
Zev A Wainberg
DEDavid Elashoff
David Elashoff
RARafael Amado
Rafael Amado
RFRichard S Finn
Richard S Finn
Stimulation of vascular endothelial growth factor (VEGF) has been observed following transarterial chemoembolization (TACE) in hepatocellular cancer (HCC) and may contribute to tumor regrowth. This pilot study examined whether intravenous (IV) bevacizumab, a monoclonal antibody against VEGF, could inhibit neovessel formation after TACE. 30 subjects with HCC undergoing TACE at a single academic institution were randomized with a computer-generated allocation in a one to one ratio to either bevacizumab at a dose of 10 mg/kg IV every 14 days beginning 1 week prior to TACE (TACE-BEV arm) or observation (TACE-O arm). Angiography was performed with TACE at day 8, and again at weeks 10 and 14. Repeat TACE was performed at week 14 if indicated. TACE-BEV subjects were allowed to continue bevacizumab beyond week 16. TACE-O subjects were allowed to cross-over to bevacizumab at week 16 in the setting of progressive disease. The main outcome measure was a comparison of neovessel formation by serial angiography. Secondary outcome measures were progression free survival (PFS) at 16 weeks, overall survival (OS), bevacizumab safety, and an analysis of VEGF levels before and after TACE with and without bevacizumab. Among the 30 subjects enrolled, 9 of 15 randomized to the TACE-O arm and 14 of 15 randomized to the TACE-BEV arm completed all 3 angiograms. At week 14, 3 of 9 (33%) TACE-O subjects and 2 of 14 (14%) TACE-BEV subjects demonstrated neovascularity. The PFS at 16 weeks was 0.19 in the TACE-O arm and 0.79 in the TACE-BEV arm (p = 0.021). The median OS was 61 months in the TACE-O arm and 49 months in the TACE-BEV arm (p = 0.21). No life-threatening bevacizumab-related toxicities were observed. There were no substantial differences in bevacizumab pharmacokinetics compared to historical controls. Bevacizumab attenuated the increase in VEGF observed post-TACE. IV bevacizumab was well tolerated in selected HCC subjects undergoing TACE, and appeared to diminish neovessel formation at week 14. ClinicalTrials.gov NCT00049322 .

1 January 2015 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
PDF file
CYColin J Yi
Colin J Yi
CWColin O. Wu
Colin O. Wu
MTMichael Tee
Michael Tee
CLChia-Ying Liu
Chia-Ying Liu
GVGustavo J Volpe
Gustavo J Volpe
DBDavid A Bluemke
David A Bluemke
Risk scores for cardiovascular disease (CVD) are in common use to integrate multiple cardiovascular risk factors in order to identify individuals at greatest risk for disease. The purpose of this study was to determine if individuals at greater cardiovascular risk have T1 mapping indices by cardiovascular magnetic resonance (CMR) indicative of greater myocardial fibrosis. CVD risk scores for 1208 subjects (men, 50.8%) ages 55–94 years old were evaluated in the Multiethnic Study of Atherosclerosis (MESA) at six centers. T1 times were determined at 1.5Tesla before and after gadolinium administration (0.15 mmol/kg) using a modified Look-Locker pulse sequence. The relationship between CMR measures (native T1, 12 and 25 minute post-gadolinium T1, partition coefficient and extracellular volume fraction) and 14 established different cardiovascular risk scores were determined using regression analysis. Bootstrapping analysis with analysis of variance was used to compare different CMR measures. CVD risk scores were significantly different for men and women (p < 0.001). 25 minute post gadolinium T1 time showed more statistically significant associations with risk scores (10/14 scores, 71%) compared to other CMR indices (e.g. native T1 (7/14 scores, 50%) and partition coefficient (7/14, 50%) in men. Risk scores, particularly the new 2013 AHA/ASCVD risk score, did not correlate with any CMR fibrosis index. Men with greater CVD risk had greater CMR indices of myocardial fibrosis. T1 times at greater delay time (25 minutes) showed better agreement with commonly used risk score indices compared to ECV and native T1 time. http://www.mesa-nhlbi.org/ , NCT00005487 .

1 October 2017 in American Journal of Roentgenology
Verified
Journal Article
Closed access
AGAntoinette S. Gomes
Antoinette S. Gomes
PMPhillip A. Monteleone
Phillip A. Monteleone
JSJames W. Sayre
James W. Sayre
RFRichard S. Finn
Richard S. Finn
SSSaeed Sadeghi
Saeed Sadeghi
RBRonald W. Busuttil
Ronald W. Busuttil
OBJECTIVE. We compared survival outcomes in 313 patients with unresectable hepatocellular carcinoma (HCC) treated with two different transcatheter arterial chemoembolization (TACE) regimens: triple-drug TACE or single-drug TACE using drug-eluting beads. MATERIALS AND METHODS. In this retrospective study, patient selection criteria were uniform. The triple-drug group (n = 166) underwent TACE using ethiodized oil with doxorubicin, cisplatin, and mitomycin-C with a microsphere embolic. The single-drug group (n = 147) underwent TACE using doxorubicin-eluting beads. Group characteristics were classified and analyzed, and survival was calculated using standard statistical methods. All patients were followed until death. Those undergoing orthotopic liver transplant (OLT) were also followed. RESULTS. There were no significant differences between the two groups in terms of demographics, Child-Pugh class, or Okuda stage. With patients undergoing OLT censored (n = 73), the mean (± standard error) survival in the triple-drug group was 23.49 ± 2.38 months, and the median survival was 16.00 ± 1.51 months. Mean survival in the single-drug bead group was 28.16 ± 2.75 months, and the median survival was 15.00 ± 1.50 months (p = 0.168). With patients undergoing OLT censored, the mean and median survival for the total cohort were 26.25 ± 1.97 and 15.00 ± 1.08 months, respectively. In the entire cohort that did not undergo OLT, patients with Child-Pugh class A disease survived significantly longer than did patients with Child-Pugh class B disease. Elevated α-fetoprotein levels were associated with shorter survival, and patients undergoing TACE with drug-eluting beads had shorter hospital stays. Although a greater percentage annual survival was observed in patients undergoing drug-eluting bead TACE who had Child-Pugh class A, Okuda stage I, and Barcelona Clinic Liver Cancer classes A and B disease starting at 36 months, this suggested survival advantage did not reach statistical significance. CONCLUSION. We found no significant survival difference in patients with unresectable HCC treated with triple-drug TACE compared with single-drug TACE using doxorubicin-eluting beads.

1 September 2019 in Radiology
Verified
Journal Article
Closed access
OROzair Rahman
Ozair Rahman
MMMichael Markl
Michael Markl
PBPallavi Balte
Pallavi Balte
HBHaben Berhane
Haben Berhane
CBCarmen Blanken
Carmen Blanken
RBR. Graham Barr
R. Graham Barr
Right-heart MRI with four-dimensional flow assessment helped to demonstrate that chronic obstructive pulmonary disease was not strongly associated with changes in venous flow to the right heart, bu... BackgroundChronic obstructive pulmonary disease (COPD) is associated with hemodynamic changes in the pulmonary vasculature. However, cardiac effects are not fully understood and vary by phenotype o...

11 May 2021 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
KYKimberly L. Yan
Kimberly L. Yan
AGAntoinette S. Gomes
Antoinette S. Gomes
PMPhillip A. Monteleone
Phillip A. Monteleone
RVRobert S. Venick
Robert S. Venick
SMSue V. McDiarmid
Sue V. McDiarmid
DFDouglas G. Farmer
Douglas G. Farmer

1 December 2009 in American Journal of Roentgenology
Verified
Journal Article
Closed access
AGAntoinette S. Gomes
Antoinette S. Gomes
MRMichael H. Rosove
Michael H. Rosove
PRPeter J. Rosen
Peter J. Rosen
RARafael G. Amado
Rafael G. Amado
JSJames W. Sayre
James W. Sayre
RBRonald W. Busuttil
Ronald W. Busuttil
OBJECTIVE. The objective of our study was to describe survival outcome in 124 patients with unresectable hepatocellular carcinoma treated with triple-drug transcatheter arterial chemoembolization (TACE) using doxorubicin, cisplatin, and mitomycin C using a standardized regimen.MATERIALS AND METHODS. One hundred twenty-four patients underwent TACE using a standardized triple-drug regimen. Embolization was performed using subselective coaxial embolization technique. Fifty-six patients (group 1) received triple-drug TACE in conjunction with a nonpermanent embolic agent, microfibrillar collagen (Avitene), and 68 patients (group 2) had triple-drug TACE with a permanent embolic agent, Embosphere Microspheres.RESULTS. Twenty-eight patients underwent liver transplantation after TACE, and survival in these patients was significantly longer than those who did not receive a transplant (p ≤ 0.001). The mean survival for the no-transplant group (n = 96) was longer in patients with Child-Pugh class A cirrhosis than in ...